187 related articles for article (PubMed ID: 16818665)
1. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study.
Gormally E; Vineis P; Matullo G; Veglia F; Caboux E; Le Roux E; Peluso M; Garte S; Guarrera S; Munnia A; Airoldi L; Autrup H; Malaveille C; Dunning A; Overvad K; Tjønneland A; Lund E; Clavel-Chapelon F; Boeing H; Trichopoulou A; Palli D; Krogh V; Tumino R; Panico S; Bueno-de-Mesquita HB; Peeters PH; Pera G; Martinez C; Dorronsoro M; Barricarte A; Navarro C; Quirós JR; Hallmans G; Day NE; Key TJ; Saracci R; Kaaks R; Riboli E; Hainaut P
Cancer Res; 2006 Jul; 66(13):6871-6. PubMed ID: 16818665
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer.
Samowitz WS; Wolff RK; Ma KN; Andersen K; Caan B; Slattery ML
Mutat Res; 2006 Mar; 595(1-2):117-24. PubMed ID: 16448675
[TBL] [Abstract][Full Text] [Related]
3. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability.
Swisher EM; Peiffer-Schneider S; Mutch DG; Herzog TJ; Rader JS; Elbendary A; Goodfellow PJ
Cancer; 1999 Jan; 85(1):119-26. PubMed ID: 9921983
[TBL] [Abstract][Full Text] [Related]
4. DNA adducts and lung cancer risk: a prospective study.
Peluso M; Munnia A; Hoek G; Krzyzanowski M; Veglia F; Airoldi L; Autrup H; Dunning A; Garte S; Hainaut P; Malaveille C; Gormally E; Matullo G; Overvad K; Raaschou-Nielsen O; Clavel-Chapelon F; Linseisen J; Boeing H; Trichopoulou A; Trichopoulos D; Kaladidi A; Palli D; Krogh V; Tumino R; Panico S; Bueno-De-Mesquita HB; Peeters PH; Kumle M; Gonzalez CA; Martinez C; Dorronsoro M; Barricarte A; Navarro C; Quiros JR; Berglund G; Janzon L; Jarvholm B; Day NE; Key TJ; Saracci R; Kaaks R; Riboli E; Vineis P
Cancer Res; 2005 Sep; 65(17):8042-8. PubMed ID: 16140979
[TBL] [Abstract][Full Text] [Related]
5. Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status.
Giaretti W; Venesio T; Sciutto A; Prevosto C; Geido E; Risio M
Genes Chromosomes Cancer; 2003 Jun; 37(2):207-13. PubMed ID: 12696070
[TBL] [Abstract][Full Text] [Related]
6. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.
Ryan BM; Lefort F; McManus R; Daly J; Keeling PW; Weir DG; Kelleher D
Gut; 2003 Jan; 52(1):101-8. PubMed ID: 12477769
[TBL] [Abstract][Full Text] [Related]
8. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
9. TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract.
Yang HK; Linnoila RI; Conrad NK; Krasna MJ; Aisner SC; Johnson BE; Kelley MJ
Int J Cancer; 1995 Aug; 64(4):229-33. PubMed ID: 7657384
[TBL] [Abstract][Full Text] [Related]
10. Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer.
Ferraz JM; Zinzindohoué F; Lecomte T; Cugnenc PH; Loriot MA; Beaune P; Stücker I; Berger A; Laurent-Puig P
Int J Cancer; 2004 Jun; 110(2):183-7. PubMed ID: 15069679
[TBL] [Abstract][Full Text] [Related]
11. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A.
Samouëlian V; Maugard CM; Jolicoeur M; Bertrand R; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Chemother Pharmacol; 2004 Dec; 54(6):497-504. PubMed ID: 15258697
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases.
Trevisiol C; Di Fabio F; Nascimbeni R; Peloso L; Salbe C; Ferruzzi E; Salerni B; Gion M
Int J Biol Markers; 2006; 21(4):223-8. PubMed ID: 17177160
[TBL] [Abstract][Full Text] [Related]
14. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers and rectal cancer: support for an inflammation-related pathway.
Slattery ML; Wolff RK; Herrick J; Caan BJ; Samowitz W
Int J Cancer; 2009 Oct; 125(7):1698-704. PubMed ID: 19452524
[TBL] [Abstract][Full Text] [Related]
16. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Sommerer F; Vieth M; Markwarth A; Röhrich K; Vomschloss S; May A; Ell C; Stolte M; Hengge UR; Wittekind C; Tannapfel A
Oncogene; 2004 Jan; 23(2):554-8. PubMed ID: 14724583
[TBL] [Abstract][Full Text] [Related]
17. p53 and K-ras mutations in lung cancers from former and never-smoking women.
Vähäkangas KH; Bennett WP; Castrén K; Welsh JA; Khan MA; Blömeke B; Alavanja MC; Harris CC
Cancer Res; 2001 Jun; 61(11):4350-6. PubMed ID: 11389059
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Mechanic LE; Marrogi AJ; Welsh JA; Bowman ED; Khan MA; Enewold L; Zheng YL; Chanock S; Shields PG; Harris CC
Carcinogenesis; 2005 Mar; 26(3):597-604. PubMed ID: 15564288
[TBL] [Abstract][Full Text] [Related]
19. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary.
Anna L; Holmila R; Kovács K; Gyorffy E; Gyori Z; Segesdi J; Minárovits J; Soltész I; Kostic S; Csekeo A; Husgafvel-Pursiainen K; Schoket B
Mutagenesis; 2009 Nov; 24(6):475-80. PubMed ID: 19643813
[TBL] [Abstract][Full Text] [Related]
20. Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology.
Shi C; Chandrasekaran A; Thuluvath PJ; Karikari C; Argani P; Goggins M; Maitra A; Eshleman JR
J Mol Diagn; 2009 Nov; 11(6):583-9. PubMed ID: 19815696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
